Barclays
TGTX icon

Barclays’s TG Therapeutics TGTX Stock Holding History

Barclays’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-49,400
Closed -$879K – 5477
2024
Q2 		$879K Buy
+49,400
New +$788K ﹤0.01% 2678
2023
Q1 		– Sell
-194,100
Closed -$2.3M – 5342
2022
Q4 		$2.3M Buy
+194,100
New +$1.41M ﹤0.01% 2176

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Barclays's TGTX Position: Q1 2026 in Review

Barclays reduced its TG Therapeutics (TGTX) stake by 74% in Q1 2026, selling an estimated $9.84M and leaving 116,657 shares worth $3.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1976.

Barclays first reported a position in TGTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $22.3M in Q2 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Barclays held 116,657 shares of TG Therapeutics worth $3.88M as of Q1 2026.
  • Barclays sold 330,063 TG Therapeutics shares in Q1 2026, an estimated $9.84M.
  • TG Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1976 holding.
  • Barclays first reported a position in TG Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Barclays's TG Therapeutics position peaked at $22.3M in Q2 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.